bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾

±´ÄªËհݵ¥¿¹ÊÇÕý´óÌìÇç×ÔÖ÷Ñз¢µÄÒ»¿îÈ«ÐÂÐòÁеÄÁ¢ÒìÈËÔ´»¯¿¹PD-L1µ¥¿Ë¡¿¹Ì壬£¬£¬£¬£¬¿É×èÖ¹PD-L1ÓëTϸ°ûÍâòµÄPD-1ºÍB7.1ÊÜÌå͎ᣬ£¬£¬£¬£¬Ê¹Tϸ°û»Ö¸´ÉúÐÔ£¬£¬£¬£¬£¬´Ó¶øÔöÇ¿ÃâÒßÓ¦´ð£¬£¬£¬£¬£¬±»ÒÔΪ¾ßÓжàÖÖÖ×ÁöµÄÖÎÁÆDZÁ¦^[1-4]¡£¡£¡£¡£¡£¡£¡£°²ÂÞÌæÄáÊÇÕý´óÌìÇçÑз¢µÄÐÂÐÍС·Ö×Ó¶à°ÐµãÀÒ°±ËἤøÒÖÖƼÁ£¬£¬£¬£¬£¬2018Äê5ÔÂÒÔÀ´ÒѽÐø»ñÅúÍíÆÚ·ÇСϸ°û·Î°©¡¢Èí×éÖ¯ÈâÁö¡¢ÈýÏßСϸ°û·Î°©¡¢¼××´ÏÙËèÑù°©ºÍ·Ö½âÐͼ××´ÏÙ°©µÈÎå¸ö˳Ӧ֢¡£¡£¡£¡£¡£¡£¡£

³ýÁËÆÕ±éÆÚСϸ°û·Î°©£¬£¬£¬£¬£¬±´ÄªËհݵ¥¿¹Óë°²ÂÞÌæÄáÁªÓÃÖÎÁƸ´·¢ÐÔ»òתÒÆÐÔ×Ó¹¬ÄÚĤ°©µÄ˳Ӧ֢ҲÒÑÓÚ½ñÄê2ÔÂÉ걨ÉÏÊУ¬£¬£¬£¬£¬²¢±»¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©ÄÉÈëÓÅÏÈÉóÆÀÉóÅú³ÌÐò¡£¡£¡£¡£¡£¡£¡£Í¬Ê±£¬£¬£¬£¬£¬ÔçÔÚ2022Äê4Ô£¬£¬£¬£¬£¬¸ÃÁÆ·¨Òѱ»CDEÁÐΪͻÆÆÐÔÖÎÁÆÆ·ÖÖ¡£¡£¡£¡£¡£¡£¡£

·Î°©ÊÇÎÒ¹ú¶ñÐÔÖ×Áö·¢²¡ºÍéæÃüµÄÊ×λԵ¹ÊÔ­ÓÉ¡£¡£¡£¡£¡£¡£¡£´Ó²¡ÀíºÍÖÎÁƽǶÈ£¬£¬£¬£¬£¬·Î°©´óÖ¿ÉÒÔ·ÖΪ·ÇСϸ°û·Î°©£¨NSCLC£©ºÍСϸ°û·Î°©£¨SCLC£©Á½´óÀà¡£¡£¡£¡£¡£¡£¡£ÖйúÁÙ´²Ö×Áöѧ»á£¨CSCO£©Ðû²¼µÄ¡¶Ð¡Ï¸°û·Î°©ÕïÁÆÖ¸ÄÏ2023¡·ÏÔʾ£¬£¬£¬£¬£¬Ð¡Ï¸°û·Î°©Õ¼·Î°©µÄ13-17%£¬£¬£¬£¬£¬ÓÉÓÚСϸ°û·Î°©¶ñÐÔˮƽ¸ß£¬£¬£¬£¬£¬ÔçÆÚ¼«Ò×±¬·¢Ô¶´¦×ªÒÆ£¬£¬£¬£¬£¬È·Õïʱ¶àΪÍíÆÚ£¬£¬£¬£¬£¬Ô¤ºó¼«²î^[5]¡£¡£¡£¡£¡£¡£¡£

2023ÄêÌìÏ·ΰ©´ó»á£¨WCLC£©ÉÏÐû²¼µÄÒ»ÏîËæ»ú¡¢Ë«Ã¤¡¢Æ½ÐбÈÕÕ¡¢¶àÖÐÐĵÄIIIÆÚÁÙ´²ÊÔÑéÏÔʾ£¬£¬£¬£¬£¬×èÖ¹2022Äê5ÔÂ14ÈÕ£¬£¬£¬£¬£¬Èë×é½ÓÊܱ´ÄªËհݵ¥¿¹ÍŽᰲÂÞÌæÄá¡¢¿¨²¬ºÍÒÀÍв´ÜÕËÄÒ©ÍŽá¼Æ»®ÖÎÁƵÄ246ÀýÆÕ±éÆÚSCLC»¼Õߣ¬£¬£¬£¬£¬ÖÐλÎÞÏ£ÍûÉúÑÄÆÚ£¨mPFS£©´ï6.9¸öÔ£¬£¬£¬£¬£¬ÖÐλ×ÜÉúÑÄÆÚ (mOS) ´ï19.3¸öÔ£¬£¬£¬£¬£¬¶ø´¿´â»¯ÁÆ×é»®·ÖΪ4.2¸öÔºÍ11.9¸öÔ£¬£¬£¬£¬£¬²î±ðÏÔÖø^[6]¡£¡£¡£¡£¡£¡£¡£ÉÏÊöÑо¿ÊÇÃâÒßÖÎÁÆÍŽữÁÆ»ù´¡ÉÏÔöÌí¿¹Ñª¹ÜÒ©ÎïÖÎÁÆģʽÔÚÆÕ±éÆÚSCLCÖÎÁÆÖеÄÊ×´ÎÀֳɣ¬£¬£¬£¬£¬Ò²ÊÇÏÖÔÚÒÑÐû²¼Êý¾ÝÖÐmPFSºÍmOS×µÄÖÎÁƼƻ®^[7] ¡£¡£¡£¡£¡£¡£¡£

bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾Ê×ϯִÐг¤¡¢Õý´óÌìÇçÒ©Òµ¼¯ÍŶ­Ê³¤Ð»³ÐÈóÌåÏÖ£º“ÎÒÃÇÒ»Ö±½«ÁÙ´²¼ÛÖµÊÓΪҩƷÑз¢µÄÖ÷Òªµ¼Ïò£¬£¬£¬£¬£¬±´ÄªËհݵ¥¿¹ÍŽᰲÂÞÌæÄá¼°»¯ÁƵÄËÄÒ©¼Æ»®ÔÚÒ»ÏßÆÕ±éÆÚСϸ°û·Î°©Ë³Ó¦Ö¢È¡µÃÁËÓÅÒìµÄÁÙ´²Êý¾Ý£¬£¬£¬£¬£¬½«¸ø»¼Õß´øÀ´È«ÐµÄÖÎÁÆÑ¡Ôñ¡£¡£¡£¡£¡£¡£¡£²»µ«ÔÆÔÆ£¬£¬£¬£¬£¬°üÀ¨×Ó¹¬ÄÚĤ°©¡¢Éöϸ°û°©µÈ¶à¸ö˳Ӧ֢µÄÁªÓüƻ®Ò²ÔÚÁÙ´²ÊÔÑéÖУ¬£¬£¬£¬£¬Î´À´½«½øÒ»²½¸»ºñÎÒÃÇÔÚÖ×ÁöÁìÓòµÄ²úÆ·¹ÜÏߣ¬£¬£¬£¬£¬Ô츣¸ü¶à»¼Õß¡£¡£¡£¡£¡£¡£¡£”

²Î¿¼ÎÄÏ×£º

1. Zhou, Jun, et al. Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Hepatology 77.1 (2023): 65-76.

2.Zhou, Jun, et al. Anlotinib plus TQB2450 in patients with advanced refractory biliary tract cancer (BTC): An open-label, dose-escalating, and dose-expansion cohort of phase Ib trial. (2021): 292-292.

3.Lan, Chunyan, et al. Anlotinib in combination with TQB2450 in patients with platinum-resistant or platinum-refractory ovarian cancer (ACTION): a multicenter, single-arm, open-label, phase 1b trial. (2021).

4.Wang, Jiayu, et al. A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer. (2021): 1074-1074.

5.¡¶ÖйúÁÙ´²Ö×Áöѧ»á£¨CSCO£©Ð¡Ï¸°û·Î°©ÕïÁÆÖ¸ÄÏ2023¡·.

6. Cheng Y, Yang R, Chen J, et al. Benmelstobart with anlotinib plus chemotherapy as first-line therapy for ES-SCLC: a randomized, double-blind, phase III trial (ETER701). Presented at: 2023 World Lung Cancer Conference; September 9-12, 2023; Singapore, Republic of Singapore. OA01.03.

7.Benmelstobart Ups ES-SCLC Survival. Cancer Discov. 2023 Nov 1;13(11): 2296-2297.

ÉùÃ÷£º

1. ±¾ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷£¬£¬£¬£¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬£¬£¬£¬£¬·Ç¹ã¸æÓÃ;¡£¡£¡£¡£¡£¡£¡£

2. ±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£¡£¡£¡£¡£¡£¡£

3. ±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬£¬£¬£¬£¬²»¿ÉÒÔÈκη½·¨È¡´úרҵµÄÒ½ÁÆÖ¸µ¼£¬£¬£¬£¬£¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£¡£¡£¡£¡£¡£¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢£¬£¬£¬£¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£¡£¡£¡£¡£¡£¡£

Ç°Õ°ÐÔÉùÃ÷£º

±¾ÐÂΟåÖаüÀ¨Èô¸ÉÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬°üÀ¨Óйء¾±´ÄªËհݵ¥¿¹×¢ÉäÒº¡¿µÄÁÙ´²¿ª·¢ÍýÏë¡¢ÁÙ´²»ñÒæÓëÓÅÊƵÄÔ¤ÆÚ¡¢ÉÌÒµ»¯Õ¹Íû¡¢»¼ÕßÁÙ´²»ñÒæ¿ÉÄÜÐÔ£¬£¬£¬£¬£¬ÒÔ¼°Ç±ÔÚÉÌҵʱ»úµÈÉùÃ÷¡£¡£¡£¡£¡£¡£¡£“Ô¤ÆÚ”¡¢“ÐÅÍД¡¢“¼ÌÐø”¡¢“¿ÉÄÜ”¡¢“Ô¤¼Æ”¡¢“ÆÚÍû”¡¢“ÓÐÍû”¡¢“ÍýÏ딡¢“ÍýÏ딡¢“DZÔÚ”¡¢“Õ¹Íû”¡¢“Ô¤¼Æ”¡¢“Ó¦¸Ã”¡¢“½«”¡¢“Ä┡¢“»á”ºÍÀàËƱí´ïÖ¼ÔÚʶ±ðÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬µ«²¢·ÇËùÓÐÇ°Õ°ÐÔ³ÂÊö¶¼°üÀ¨ÕâЩʶ±ð´Ê¡£¡£¡£¡£¡£¡£¡£ÕâЩǰհÐÔ³ÂÊöΪ¹«Ë¾»ùÓÚÄ¿½ñËùÕÆÎÕµÄÊý¾ÝºÍÐÅÏ¢Ëù×öµÄÕ¹Íû»òÆÚÍû£¬£¬£¬£¬£¬¿ÉÄÜÒòÊܵ½Õþ²ß¡¢Ñз¢¡¢Êг¡¼°î¿ÏµµÈ²»È·¶¨ÒòËØ»òΣº¦µÄÓ°Ï죬£¬£¬£¬£¬¶øµ¼ÖÂÏÖʵЧ¹ûÓëÇ°Õ°ÐÔ³ÂÊöÓÐÖØ´ó²î±ð¡£¡£¡£¡£¡£¡£¡£ÇëÏÖÓлòDZÔÚµÄͶ×ÊÕßÉóÉ÷˼Á¿¿ÉÄܱ£´æµÄΣº¦£¬£¬£¬£¬£¬²¢²»¿ÉÍêÈ«ÒÀÀµ±¾ÐÂΟåÖеÄÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬¸ÃµÈ³ÂÊö°üÀ¨ÐÅÏ¢½ö¼°ÓÚ±¾ÐÂΟåÐû²¼µ±ÈÕ¡£¡£¡£¡£¡£¡£¡£³ý·ÇÖ´·¨ÒªÇ󣬣¬£¬£¬£¬±¾¹«Ë¾ÎÞÒåÎñÒòÐÂÐÅÏ¢¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐζø¶Ô±¾ÐÂΟåÖÐÈκÎÇ°Õ°ÐÔ³ÂÊö¾ÙÐиüлòÐ޸ġ£¡£¡£¡£¡£¡£¡£